Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
[...]the use of this approach depends on the SARS-CoV-2 variant.1 Because of the rapidly changing variants, in-vitro neutralisation data using relative fold-changes in effective concentration (EC50) are frequently used to decide whether a given monoclonal antibody will be effective for a variant.2 H...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2023-05, Vol.23 (5), p.528-530 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 530 |
|---|---|
| container_issue | 5 |
| container_start_page | 528 |
| container_title | The Lancet infectious diseases |
| container_volume | 23 |
| creator | Solera, Javier T Arbol, Berta G Ferreira, Victor H Kurtesi, Alexandra Hu, Queenie Ierullo, Matthew Valverde-Zuniga, Adriana Raslan, Ismail Nasir, Asma Grizales, Clara Hardy, W Rod Kulasingam, Vathany Gingras, Anne-Claude Humar, Atul Kumar, Deepali |
| description | [...]the use of this approach depends on the SARS-CoV-2 variant.1 Because of the rapidly changing variants, in-vitro neutralisation data using relative fold-changes in effective concentration (EC50) are frequently used to decide whether a given monoclonal antibody will be effective for a variant.2 However, these data are difficult to interpret if the serum concentration of the monoclonal antibody is not known. [...]a more clinically relevant way is to directly test variant-specific neutralisation from serum samples obtained from patients who have received the monoclonal antibody (in-vivo method). Before receiving tixagevimab–cilgavimab, 30 (40%) of 75 patients had detectable neutralisation against omicron BA.4/5, 25 (33·3%) had detectable neutralization against BQ.1.1, and 19 (25·3%) had detectable neutralisation against XBB.1.5. Since both BQ.1.1 and XBB.1.5 evade immunity conferred by vaccination, the presence of baseline neutralisation might have been driven by previous infection.6 Patients with documented previous COVID-19 infection were more likely at baseline to have BQ.1.1 neutralisation (odds ratio [OR] 4·1, 95% CI 1·3–12·7) and XBB.1.5 neutralisation (OR 5·4, 95% CI 1·7–17·4). The study was funded in part by the COVID-19 Immunity Task Force via the Public Health Agency of Canada (grant number 2122-HQ-000067 to DK). |
| doi_str_mv | 10.1016/S1473-3099(23)00208-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10076000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309923002086</els_id><sourcerecordid>2798714420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4116-24fa7b728e877d2f6dbebf9c357e60f37a00874a193fab5c29dd2ec396f941183</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhSMEoqXwCCBLbNpF4NpO4mSFqlJ-pEosgLXlONczt0riYCfDdMc78IY8CZ6ZUn42rHxtn3t8j78se8rhBQdevfzICyVzCU1zKuQZgIA6r-5lx-m4yIuiVPf39UFylD2K8RqAKw7Fw-xIKpAgeX2cbV-TcxhwnMn0LGJYBjbiMgfTUzQz-ZF5x_xANqQyLm1PI5oVRkYjm5IgdUYW0CJtaFyxKfhpfdObLUX2leY1m2mb5BsaTPvj23dL_crsN4-zB870EZ_crifZ5zeXny7e5Vcf3r6_OL_KbcF5lYvCGdUqUWOtVCdc1bXYusbKUmEFTioDUKvC8EY605ZWNF0n0Mqmck0yqOVJ9urgOy3tgJ1N86ZsegppiHCjvSH9981Ia73yG80BVAUAyeH01iH4LwvGWQ8ULfa9GdEvUQvV1IoXhdhJn_8jvfZLGFM-LWqQCUVZq6QqD6r0pzEGdHfTcNA7uHoPV-_IaSH1Hq6uUt-zP6Pcdf2i-Tsrpg_dEAYdbQJksaNEaNadp_888RN43bjH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2803309587</pqid></control><display><type>article</type><title>Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Solera, Javier T ; Arbol, Berta G ; Ferreira, Victor H ; Kurtesi, Alexandra ; Hu, Queenie ; Ierullo, Matthew ; Valverde-Zuniga, Adriana ; Raslan, Ismail ; Nasir, Asma ; Grizales, Clara ; Hardy, W Rod ; Kulasingam, Vathany ; Gingras, Anne-Claude ; Humar, Atul ; Kumar, Deepali</creator><creatorcontrib>Solera, Javier T ; Arbol, Berta G ; Ferreira, Victor H ; Kurtesi, Alexandra ; Hu, Queenie ; Ierullo, Matthew ; Valverde-Zuniga, Adriana ; Raslan, Ismail ; Nasir, Asma ; Grizales, Clara ; Hardy, W Rod ; Kulasingam, Vathany ; Gingras, Anne-Claude ; Humar, Atul ; Kumar, Deepali</creatorcontrib><description>[...]the use of this approach depends on the SARS-CoV-2 variant.1 Because of the rapidly changing variants, in-vitro neutralisation data using relative fold-changes in effective concentration (EC50) are frequently used to decide whether a given monoclonal antibody will be effective for a variant.2 However, these data are difficult to interpret if the serum concentration of the monoclonal antibody is not known. [...]a more clinically relevant way is to directly test variant-specific neutralisation from serum samples obtained from patients who have received the monoclonal antibody (in-vivo method). Before receiving tixagevimab–cilgavimab, 30 (40%) of 75 patients had detectable neutralisation against omicron BA.4/5, 25 (33·3%) had detectable neutralization against BQ.1.1, and 19 (25·3%) had detectable neutralisation against XBB.1.5. Since both BQ.1.1 and XBB.1.5 evade immunity conferred by vaccination, the presence of baseline neutralisation might have been driven by previous infection.6 Patients with documented previous COVID-19 infection were more likely at baseline to have BQ.1.1 neutralisation (odds ratio [OR] 4·1, 95% CI 1·3–12·7) and XBB.1.5 neutralisation (OR 5·4, 95% CI 1·7–17·4). The study was funded in part by the COVID-19 Immunity Task Force via the Public Health Agency of Canada (grant number 2122-HQ-000067 to DK).</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(23)00208-6</identifier><identifier>PMID: 37030318</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Antibodies, Monoclonal ; Clinical trials ; Coronaviruses ; Correspondence ; COVID-19 ; Humans ; Immunity ; Infections ; Infectious diseases ; Monoclonal antibodies ; Neutralization ; Prophylaxis ; Public health ; SARS-CoV-2 - drug effects ; Severe acute respiratory syndrome coronavirus 2 ; Vaccination</subject><ispartof>The Lancet infectious diseases, 2023-05, Vol.23 (5), p.528-530</ispartof><rights>2023 Elsevier Ltd</rights><rights>2023. Elsevier Ltd</rights><rights>2023 Elsevier Ltd. All rights reserved. 2023 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4116-24fa7b728e877d2f6dbebf9c357e60f37a00874a193fab5c29dd2ec396f941183</citedby><cites>FETCH-LOGICAL-c4116-24fa7b728e877d2f6dbebf9c357e60f37a00874a193fab5c29dd2ec396f941183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309923002086$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37030318$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Solera, Javier T</creatorcontrib><creatorcontrib>Arbol, Berta G</creatorcontrib><creatorcontrib>Ferreira, Victor H</creatorcontrib><creatorcontrib>Kurtesi, Alexandra</creatorcontrib><creatorcontrib>Hu, Queenie</creatorcontrib><creatorcontrib>Ierullo, Matthew</creatorcontrib><creatorcontrib>Valverde-Zuniga, Adriana</creatorcontrib><creatorcontrib>Raslan, Ismail</creatorcontrib><creatorcontrib>Nasir, Asma</creatorcontrib><creatorcontrib>Grizales, Clara</creatorcontrib><creatorcontrib>Hardy, W Rod</creatorcontrib><creatorcontrib>Kulasingam, Vathany</creatorcontrib><creatorcontrib>Gingras, Anne-Claude</creatorcontrib><creatorcontrib>Humar, Atul</creatorcontrib><creatorcontrib>Kumar, Deepali</creatorcontrib><title>Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>[...]the use of this approach depends on the SARS-CoV-2 variant.1 Because of the rapidly changing variants, in-vitro neutralisation data using relative fold-changes in effective concentration (EC50) are frequently used to decide whether a given monoclonal antibody will be effective for a variant.2 However, these data are difficult to interpret if the serum concentration of the monoclonal antibody is not known. [...]a more clinically relevant way is to directly test variant-specific neutralisation from serum samples obtained from patients who have received the monoclonal antibody (in-vivo method). Before receiving tixagevimab–cilgavimab, 30 (40%) of 75 patients had detectable neutralisation against omicron BA.4/5, 25 (33·3%) had detectable neutralization against BQ.1.1, and 19 (25·3%) had detectable neutralisation against XBB.1.5. Since both BQ.1.1 and XBB.1.5 evade immunity conferred by vaccination, the presence of baseline neutralisation might have been driven by previous infection.6 Patients with documented previous COVID-19 infection were more likely at baseline to have BQ.1.1 neutralisation (odds ratio [OR] 4·1, 95% CI 1·3–12·7) and XBB.1.5 neutralisation (OR 5·4, 95% CI 1·7–17·4). The study was funded in part by the COVID-19 Immunity Task Force via the Public Health Agency of Canada (grant number 2122-HQ-000067 to DK).</description><subject>Antibodies, Monoclonal</subject><subject>Clinical trials</subject><subject>Coronaviruses</subject><subject>Correspondence</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Immunity</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Monoclonal antibodies</subject><subject>Neutralization</subject><subject>Prophylaxis</subject><subject>Public health</subject><subject>SARS-CoV-2 - drug effects</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccination</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkc1u1DAUhSMEoqXwCCBLbNpF4NpO4mSFqlJ-pEosgLXlONczt0riYCfDdMc78IY8CZ6ZUn42rHxtn3t8j78se8rhBQdevfzICyVzCU1zKuQZgIA6r-5lx-m4yIuiVPf39UFylD2K8RqAKw7Fw-xIKpAgeX2cbV-TcxhwnMn0LGJYBjbiMgfTUzQz-ZF5x_xANqQyLm1PI5oVRkYjm5IgdUYW0CJtaFyxKfhpfdObLUX2leY1m2mb5BsaTPvj23dL_crsN4-zB870EZ_crifZ5zeXny7e5Vcf3r6_OL_KbcF5lYvCGdUqUWOtVCdc1bXYusbKUmEFTioDUKvC8EY605ZWNF0n0Mqmck0yqOVJ9urgOy3tgJ1N86ZsegppiHCjvSH9981Ia73yG80BVAUAyeH01iH4LwvGWQ8ULfa9GdEvUQvV1IoXhdhJn_8jvfZLGFM-LWqQCUVZq6QqD6r0pzEGdHfTcNA7uHoPV-_IaSH1Hq6uUt-zP6Pcdf2i-Tsrpg_dEAYdbQJksaNEaNadp_888RN43bjH</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Solera, Javier T</creator><creator>Arbol, Berta G</creator><creator>Ferreira, Victor H</creator><creator>Kurtesi, Alexandra</creator><creator>Hu, Queenie</creator><creator>Ierullo, Matthew</creator><creator>Valverde-Zuniga, Adriana</creator><creator>Raslan, Ismail</creator><creator>Nasir, Asma</creator><creator>Grizales, Clara</creator><creator>Hardy, W Rod</creator><creator>Kulasingam, Vathany</creator><creator>Gingras, Anne-Claude</creator><creator>Humar, Atul</creator><creator>Kumar, Deepali</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230501</creationdate><title>Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab</title><author>Solera, Javier T ; Arbol, Berta G ; Ferreira, Victor H ; Kurtesi, Alexandra ; Hu, Queenie ; Ierullo, Matthew ; Valverde-Zuniga, Adriana ; Raslan, Ismail ; Nasir, Asma ; Grizales, Clara ; Hardy, W Rod ; Kulasingam, Vathany ; Gingras, Anne-Claude ; Humar, Atul ; Kumar, Deepali</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4116-24fa7b728e877d2f6dbebf9c357e60f37a00874a193fab5c29dd2ec396f941183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Monoclonal</topic><topic>Clinical trials</topic><topic>Coronaviruses</topic><topic>Correspondence</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Immunity</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Monoclonal antibodies</topic><topic>Neutralization</topic><topic>Prophylaxis</topic><topic>Public health</topic><topic>SARS-CoV-2 - drug effects</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Solera, Javier T</creatorcontrib><creatorcontrib>Arbol, Berta G</creatorcontrib><creatorcontrib>Ferreira, Victor H</creatorcontrib><creatorcontrib>Kurtesi, Alexandra</creatorcontrib><creatorcontrib>Hu, Queenie</creatorcontrib><creatorcontrib>Ierullo, Matthew</creatorcontrib><creatorcontrib>Valverde-Zuniga, Adriana</creatorcontrib><creatorcontrib>Raslan, Ismail</creatorcontrib><creatorcontrib>Nasir, Asma</creatorcontrib><creatorcontrib>Grizales, Clara</creatorcontrib><creatorcontrib>Hardy, W Rod</creatorcontrib><creatorcontrib>Kulasingam, Vathany</creatorcontrib><creatorcontrib>Gingras, Anne-Claude</creatorcontrib><creatorcontrib>Humar, Atul</creatorcontrib><creatorcontrib>Kumar, Deepali</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Solera, Javier T</au><au>Arbol, Berta G</au><au>Ferreira, Victor H</au><au>Kurtesi, Alexandra</au><au>Hu, Queenie</au><au>Ierullo, Matthew</au><au>Valverde-Zuniga, Adriana</au><au>Raslan, Ismail</au><au>Nasir, Asma</au><au>Grizales, Clara</au><au>Hardy, W Rod</au><au>Kulasingam, Vathany</au><au>Gingras, Anne-Claude</au><au>Humar, Atul</au><au>Kumar, Deepali</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>23</volume><issue>5</issue><spage>528</spage><epage>530</epage><pages>528-530</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>[...]the use of this approach depends on the SARS-CoV-2 variant.1 Because of the rapidly changing variants, in-vitro neutralisation data using relative fold-changes in effective concentration (EC50) are frequently used to decide whether a given monoclonal antibody will be effective for a variant.2 However, these data are difficult to interpret if the serum concentration of the monoclonal antibody is not known. [...]a more clinically relevant way is to directly test variant-specific neutralisation from serum samples obtained from patients who have received the monoclonal antibody (in-vivo method). Before receiving tixagevimab–cilgavimab, 30 (40%) of 75 patients had detectable neutralisation against omicron BA.4/5, 25 (33·3%) had detectable neutralization against BQ.1.1, and 19 (25·3%) had detectable neutralisation against XBB.1.5. Since both BQ.1.1 and XBB.1.5 evade immunity conferred by vaccination, the presence of baseline neutralisation might have been driven by previous infection.6 Patients with documented previous COVID-19 infection were more likely at baseline to have BQ.1.1 neutralisation (odds ratio [OR] 4·1, 95% CI 1·3–12·7) and XBB.1.5 neutralisation (OR 5·4, 95% CI 1·7–17·4). The study was funded in part by the COVID-19 Immunity Task Force via the Public Health Agency of Canada (grant number 2122-HQ-000067 to DK).</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>37030318</pmid><doi>10.1016/S1473-3099(23)00208-6</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2023-05, Vol.23 (5), p.528-530 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10076000 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies, Monoclonal Clinical trials Coronaviruses Correspondence COVID-19 Humans Immunity Infections Infectious diseases Monoclonal antibodies Neutralization Prophylaxis Public health SARS-CoV-2 - drug effects Severe acute respiratory syndrome coronavirus 2 Vaccination |
| title | Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A02%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20serum%20neutralisation%20of%20omicron%20sublineages%20in%20patients%20receiving%20prophylaxis%20with%20tixagevimab%E2%80%93cilgavimab&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Solera,%20Javier%20T&rft.date=2023-05-01&rft.volume=23&rft.issue=5&rft.spage=528&rft.epage=530&rft.pages=528-530&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(23)00208-6&rft_dat=%3Cproquest_pubme%3E2798714420%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2803309587&rft_id=info:pmid/37030318&rft_els_id=S1473309923002086&rfr_iscdi=true |